申请人:Calvet James P.
公开号:US20110082098A1
公开(公告)日:2011-04-07
Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.
新比奴霉素类似物在治疗、抑制和/或预防自体显性多囊肾病(ADPKD)中的囊肿形成方法中是有用的。本公开提供了治疗ADPKD的方法,包括给予香豆素-3-羧酰胺新比奴霉素类似物的治疗有效量。因此,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低mTOR途径磷酸化蛋白P-mTOR、P-Akt和P-S6K的水平,或其组合。此外,该方法可以包括给予新比奴霉素类似物的治疗有效量,以降低Hsp-90客体蛋白CFTR、ErbB2、c-Raf和Cdk4的水平,或其组合。